Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | The delivery of niraparib and rucaparib as ovarian cancer treatment options

Mansoor Mirza • 29 Sep 2017
ESMO 2017
Gynecological Cancer Niraparib Olaparib Rucaparib

Currently, the only labelled PARP inhibitor for use in treating BRCA-mutated ovarian cancer in Europe is olaparib. Mansoor Mirza, MD, from the Copenhagen University Hospital, Copenhagen, Denmark explains his hopes that niraparib and rucaparib, two PARP inhibitors recently assessed in clinical trials, will also become available as a treatment option and discusses the socioeconomic factors associated with the introduction of these agents. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.

More from Mansoor Mirza

2:11
Long-term benefit from 1L maintenance PARP inhibitors in ovarian cancer
Mansoor Mirza • 29 Sep 2022
4:15
Optimal management of recurrent low grade endometrial cancer
Mansoor Mirza • 29 Sep 2022
2:20
ENGOT-EN1: carboplatin plus paclitaxel plus nintedanib for endometrial cancer
Mansoor Mirza • 24 Oct 2021
8:20
Immune checkpoint inhibitors for endometrial and cervical cancer
Mansoor Mirza • 24 Oct 2021

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals